KR20220130251A - 비정상적 세포 성장의 치료를 위한 조성물 및 방법 - Google Patents

비정상적 세포 성장의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220130251A
KR20220130251A KR1020227031505A KR20227031505A KR20220130251A KR 20220130251 A KR20220130251 A KR 20220130251A KR 1020227031505 A KR1020227031505 A KR 1020227031505A KR 20227031505 A KR20227031505 A KR 20227031505A KR 20220130251 A KR20220130251 A KR 20220130251A
Authority
KR
South Korea
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227031505A
Other languages
English (en)
Korean (ko)
Inventor
마헤쉬 파드발
폴 오콰비 칸사
Original Assignee
베라스템, 인코포레이티드
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베라스템, 인코포레이티드, 화이자 인코포레이티드 filed Critical 베라스템, 인코포레이티드
Priority to KR1020247035735A priority Critical patent/KR20240159639A/ko
Publication of KR20220130251A publication Critical patent/KR20220130251A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020227031505A 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법 Ceased KR20220130251A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247035735A KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
US61/925,467 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
KR1020167021370A KR102444494B1 (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167021370A Division KR102444494B1 (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035735A Division KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20220130251A true KR20220130251A (ko) 2022-09-26

Family

ID=52434976

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227031505A Ceased KR20220130251A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020247035735A Pending KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020167021370A Active KR102444494B1 (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247035735A Pending KR20240159639A (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법
KR1020167021370A Active KR102444494B1 (ko) 2014-01-09 2015-01-09 비정상적 세포 성장의 치료를 위한 조성물 및 방법

Country Status (15)

Country Link
US (3) US20150190346A1 (cg-RX-API-DMAC7.html)
EP (2) EP3900726A1 (cg-RX-API-DMAC7.html)
JP (5) JP6647204B2 (cg-RX-API-DMAC7.html)
KR (3) KR20220130251A (cg-RX-API-DMAC7.html)
CN (3) CN115708827A (cg-RX-API-DMAC7.html)
AU (4) AU2015204597B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016021B1 (cg-RX-API-DMAC7.html)
CA (1) CA2936283C (cg-RX-API-DMAC7.html)
DK (1) DK3091981T3 (cg-RX-API-DMAC7.html)
ES (1) ES2870562T3 (cg-RX-API-DMAC7.html)
IL (2) IL246667B (cg-RX-API-DMAC7.html)
MX (2) MX384259B (cg-RX-API-DMAC7.html)
NZ (2) NZ721934A (cg-RX-API-DMAC7.html)
SG (2) SG11201605588YA (cg-RX-API-DMAC7.html)
WO (1) WO2015106096A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019218958A1 (zh) * 2018-05-15 2019-11-21 江苏豪森药业集团有限公司 包含小分子egfr抑制剂的药物组合物及其制备方法
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
BR112022017578A2 (pt) * 2020-03-27 2022-10-18 Pfizer Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo
ES2955914T3 (es) * 2020-04-24 2023-12-11 Dr Falk Pharma Gmbh Formulación sistémica de un derivado de la piridinona para las enfermedades relacionadas con la TG2
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN117582504A (zh) * 2022-08-15 2024-02-23 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
MX366161B (es) * 2008-08-13 2019-07-01 Vertex Pharmaceutical Incorporated Composicion farmaceutica y su administracion.
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CA2808501A1 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
US9962385B2 (en) * 2014-02-07 2018-05-08 Verastem, Inc. Methods and compositions for treating abnormal cell growth
ES2987376T3 (es) * 2015-06-29 2024-11-14 Verastem Inc Composiciones terapéuticas, combinaciones y métodos de uso

Also Published As

Publication number Publication date
AU2020210153A1 (en) 2020-08-13
MX2021008225A (es) 2021-08-11
US20200038331A1 (en) 2020-02-06
SG11201605588YA (en) 2016-08-30
CN106102744A (zh) 2016-11-09
AU2015204597A1 (en) 2016-07-21
JP6647204B2 (ja) 2020-02-14
US20150190346A1 (en) 2015-07-09
BR112016016021B1 (pt) 2023-01-10
AU2025204843A1 (en) 2025-07-17
JP2025084892A (ja) 2025-06-03
AU2020210153B2 (en) 2022-07-21
NZ721934A (en) 2022-04-29
NZ760233A (en) 2022-04-29
MX2016009056A (es) 2017-01-23
EP3900726A1 (en) 2021-10-27
CA2936283C (en) 2023-02-28
IL246667A0 (en) 2016-08-31
CA2936283A1 (en) 2015-07-16
AU2015204597B2 (en) 2020-04-30
CN115708827A (zh) 2023-02-24
EP3091981B1 (en) 2021-03-10
WO2015106096A1 (en) 2015-07-16
SG10201805890QA (en) 2018-08-30
BR112016016021A8 (pt) 2018-04-17
DK3091981T3 (da) 2021-05-31
AU2022256144B2 (en) 2025-04-03
ES2870562T3 (es) 2021-10-27
IL246667B (en) 2022-05-01
IL292054A (en) 2022-06-01
EP3091981A1 (en) 2016-11-16
US20230104303A1 (en) 2023-04-06
JP2022001587A (ja) 2022-01-06
JP2023065568A (ja) 2023-05-12
KR20160104725A (ko) 2016-09-05
AU2022256144A1 (en) 2022-11-24
KR102444494B1 (ko) 2022-09-20
CN119868364A (zh) 2025-04-25
KR20240159639A (ko) 2024-11-05
JP2017502062A (ja) 2017-01-19
BR112016016021A2 (pt) 2017-09-19
MX384259B (es) 2025-03-14
JP2020007355A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
JP5835883B2 (ja) 被覆錠剤製剤
CN115243681B (zh) 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
JP2021501142A (ja) キナーゼを調節する化合物の製剤
JP2024542248A (ja) Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
CN112839656A (zh) 急性骨髓性白血病用抗肿瘤剂
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR101587140B1 (ko) 위장관 질환 치료용 모사프리드 구연산염 미니정제 함유 서방성 캡슐 제제 및 이의 제조 방법
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
RU2586290C1 (ru) Твердая лекарственная форма прокарбазина немедленного высвобождения и способ ее получения
KR20180112066A (ko) 피롤로-융합된 6-원의 헤테로시클릭 화합물을 포함하는 약학적 조성물
TW202421150A (zh) 艾魯美冷之分散體
TW202500155A (zh) 雌激素受體降解劑之固體口服劑型
BR122024022942A2 (pt) Composições farmaceuticamente aceitáveis para administração oral, comprimidos farmaceuticamente aceitáveis, usos relacionados, processo para a preparação de uma dispersão sólida, dispersão sólida e kit compreendendo a composição

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220913

Application number text: 1020167021370

Filing date: 20160804

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221013

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221018

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230506

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240527

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230506

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20221018

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I